Pediatric Asthma Programs Featuring PARI Pharma's eFlow Acquired by AstraZeneca
MONTEREY, Calif., Sept. 24 /PRNewswire/ -- Today, the rights to Verus
Pharmaceuticals' pediatric asthma development programs that utilize PARI's
eFlow electronic nebulizer for aerosol delivery were acquired by
AstraZeneca. Following Gilead Sciences' acquisition of Corus Pharma in
August 2006, ...
Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria
...as infections in patients with CF.
Pharma and the Investigational eFlow ((R)) ...nvestigational eFlow Nebulizer System developed by pari
Pharma GmbH. The investigational eFlow Nebulizer ...zer System and eFlow Technology are proprietary to pari
Pharma and can be optimized to specific drug formu...
PARI Respiratory to Present New Study Comparing Nebulizers Delivering Budesonide at CHEST 2008
...sa Cambridge, director of
clinical development for pari
Respiratory Equipment, Inc.
The study compares t... the American College of Chest Physicians.
Respiratory Equipment, Inc.
is a leading worldwide developer and manufacturer ...
Transave, Inc. Secures $12.5 Million in New Financing
...visit http://www.horizontechfinance.com .
Pharma and the Investigational eFlow Nebulizer Sys...igational eFlow Nebulizer System is
proprietary to pari
Pharma and can be optimized to specific drug
Pharma focuses on the development of aerosol deliv...
Application for Listing of Shire Limited Ordinary Shares
...me, 14,000 shares under the BioChem Pharma
Stock Option Plan and 82,000 shares under the Shire plc Sharesave Plan.
Upon issue, these shares shall rank pari
passu with all other ordinary
shares of Shire.
From today Shire plc will be registered as a private company, wholly
owned by Shire, and the listing ...
Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
...ave a 2% monthly pay in kind
dividend, restrictive covenants including a prohibition on funded debt and
the issuance of securities which are senior or pari
passu to the Series C
Preferred, are redeemable by the Registrant on February 14, 2009, and are
slated to be retired as part of the merger.
Senetek PLC Announces Appointments of Key Personnel
...sumed the position of Director of Business Development.
Most recently, Mr. Campagnoli was the Executive Director of Sales and
Business Development for pari
Pharma, a Virginia-based specialty
pharmaceutical company. He is a graduate of Western Maryland College and
holds a Masters from the University of Mar...
PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday
... MIDLOTHIAN, Va., Oct. 9 /PRNewswire/ -- pari
breath-enhanced nebulizer, the pari
LC PLUS, and PRONEB Ultra compressor
deliver Dey, ...are companies. "We are extremely pleased that our pari
LC PLUS nebulizer and PRONEB
Ultra compressor were...